Holen Sie sich die Stockscreener-App
3.29
0.60%
-0.02
Handel nachbörslich:
3.18
-0.11
-3.34%
Schlusskurs vom Vortag:
$3.31
Offen:
$3.3
24-Stunden-Volumen:
2.73M
Relative Volume:
0.87
Marktkapitalisierung:
$536.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-167.86M
KGV:
-1.4345
EPS:
-2.2935
Netto-Cashflow:
$-132.31M
1W Leistung:
-13.87%
1M Leistung:
-4.36%
6M Leistung:
+40.60%
1J Leistung:
+62.07%
1-Tages-Spanne:
$3.18
$3.32
1-Wochen-Bereich:
$3.18
$3.865
52-Wochen-Spanne:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.29 | 539.71M | 0 | -167.86M | -132.31M | -2.2935 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView
CABA Shows Promising Results in New Clinical Data - GuruFocus
CABA: Cabaletta Bio Signs Major Supply Agreement and Reports Pro - GuruFocus
Cabaletta Bio 2026 Q1 10-Q Filing: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Cabaletta Bio Unveils Promising Preconditioning-Free Rese-cel CAR-T Data and Automated Manufacturing Advances at ASGCT 2026 Annual Meeting - Minichart
Cabaletta Bio Reports Promising 2026 Q1 Results: Rese-cel CAR-T Therapy Advances, New Data & $150M Financing Highlighted - Minichart
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune (CABA) - Seeking Alpha
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Cabaletta Bio (CABA) Fairly Valued After Q1 2026? EPS -$0.39 - GuruFocus
Cabaletta Bio presents data on preconditioning-free rese-cel By Investing.com - Investing.com Australia
Cabaletta Bio Reports Encouraging RESET-PV Trial Data - TipRanks
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio presents data on preconditioning-free rese-cel - Investing.com
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - The Manila Times
Cabaletta Bio (NASDAQ: CABA) warns on going concern despite $141M cash raise - Stock Titan
Cabaletta Bio, Inc. 1Q 2026: Net loss $(43.5M), EPS $(0.39) — 10-Q Summary - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Autoimmune cell therapy push: Cabaletta raises $150M for rese-cel trials - Stock Titan
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
U.S. Earnings Preview: Before Market Open May 13 - Moomoo
TradingKey - TradingKey
Cabaletta Bio (CABA) Eps Diluted (TTM) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
Number of shareholders of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Number of shareholders of Cabaletta Bio, Inc. – BMV:CABA - TradingView
CABA Stock Pops As $30 Target, Funding And Manufacturing Align - timothysykes.com
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta Bio Announces $150 Million Equity Offering - The Globe and Mail
Cabaletta Bio prices $150 million public offering - The Pharma Letter
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting - MyChesCo
Cabaletta Bio | 8-K: Current report - Moomoo
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy - TechStock²
CABA Reiterates by Cantor Fitzgerald -- Price Target Maintained at $30 - GuruFocus
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):